C.R. Bard (NYSE:BCR) traded with a cut of -0.03 points or -0.01% at $225.34 per share. As per the last available information, the stock aggregated $26.02 million in upticks and $18.22 million in downticks, keeping the net money flow capped at $7.8 million. The up/down ratio was found to be 1.43. For the week, the shares have seen a change of 2.14% in the share price.A block trade of $5.23 million in upticks and $0 million in downticks also took place during the day. The up/down ratio for the block stood at 0. The net money flow for this transaction was $5.23 million.
Currently the company Insiders own 0.97% of C.R. Bard shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -5.91% . Institutional Investors own 93.07% of C.R. Bard shares. During last six month period, the net percent change held by insiders has seen a change of -14.77%. On the companys insider trading activities, Holland Christopher S, officer (Senior Vice President and CFO) of Bard C R Inc /Nj/, unloaded 3,970 shares at an average price of $219.88 on May 27, 2016. The total amount of the transaction was worth $872,924, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
C.R. Bard (NYSE:BCR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.03 points or 0.01% at $225.34 with 361,896 shares getting traded. Post opening the session at $225.64, the shares hit an intraday low of $225.07 and an intraday high of $226.7699 and the price was in this range throughout the day. The company has a market cap of $16,522 million and the number of outstanding shares have been calculated to be 73,318,689 shares. The 52-week high of C.R. Bard (NYSE:BCR) is $228.31 and the 52-week low is $167.36.
Many analysts have stated their opinion on the company shares. Barclays maintains their rating on the shares of C.R. Bard (NYSE:BCR). The current rating of the shares is Equalweight. Equity Analysts at the Firm raises the price target to $224 per share from $212 per share. The rating by the firm was issued on May 24, 2016.
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.